AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Medicine Advances Article
PDF (405.4 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Clinical Guideline | Open Access

Expert consensus on treatment for stage Ⅲ non-small cell lung cancer

Yi-Long Wu1,2( ), Shun Lu3, Qinghua Zhou4, Li Zhang5, Ying Cheng6, Jie Wang7, Buhai Wang8, Chengping Hu9, Lizhu Lin10, Wenzhao Zhong1, Yong Song11, Nong Yang12, Xiaorong Dong13, Jian Zhao14, Haihong Yang15, Hui Guo16, Xiaolong Yan17, Hongxu Liu18, Rui Ma18, Jie Lin19, Siyang Liu1, Chun Chen20, Lifeng Wang21, Chengzhi Zhou15, Ming Zhou14, Fang Wu22, Xue-Ning Yang1, Yingying Du23, Yu Yao16, Yang Shao24, Shaodong Hong5, Jiuwei Cui25, Xueping Quan26, Rongrong Chen27, Jiayan Wu28, Jiatao Zhang1, Jianya Zhou29, Binchao Wang1, Chao Cheng30, Huijuan Wang31, Jingjing Liu6, Lin Wu12, Yan Huang5, Yukun Kuang30, Yongchang Zhang12, Jia Hu32, Jinji Yang1, Weineng Feng33, Wenmei Su34, Yun Fan35, Fan Yang36, Ming Chen5, Kejing Tang30, Yi Pan1, Peng Shen37, Anwen Liu38, Haibo Zhang39, Wenhua Liang15, Qing Zhou1, Zhiyong Ma31, Xiuyu Cai5, Hui Liu5, Longfei Chen40, Shaokun Chuai40, Jianzhen Shan29, Yanfang Zheng14, Changxuan You37, Xiaoxia Zhu41, Li Li42, Tongmei Zhang43, Haiyan Tu1, Wurong Lin44, Xuchao Zhang1, Penghui Zhou5, Zunfu Ke30, Huiying Liang1
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Chinese Association of Lung Cancer (CALC), Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG), Guangzhou, China
Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
Lung Cancer Institute/Lung Cancer Center, West, China Hospital, Sichuan University, Chengdu, Sichuan, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Jilin Cancer Hospital, Changchun, Jilin, China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Subei People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, China
Xiangya Hospital of Central South University, Changsha, Hunan, China
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China
Jinling Hospital of Nanjing University School of Medicine, Nanjing, China
Department of Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
Union Hospital Affiliated to Tongji Medicine College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
Department of Thoracic Surgery, Tangdu Hospital, The Air Force Military Medical University, Xi'an, China
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
The Affiliated Drum Tower Hospital of Nanjing University Medicine School, Nanjing, Jiangsu, China
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
The First Affiliated Hospital of Anhui Medical University, Hefei, China
Geneseeq Technology Inc., Nanjing, Jiangsu, China
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Shanghai Tongshu Biotechnology Co., Ltd., Shanghai, China
Beijing GenePlus Technology Co., Ltd., Beijing, China
Berry Oncology Co., Ltd, Fuzhou, Fujian, China
The First Affiliated Hospital of College of Medicine of Zhejiang University, Hangzhou, Zhejian, China
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
The First People's Hospital of Foshan, Foshan, Guangdong, China
Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Peking University People's Hospital, Beijing, China
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
Guangzhou Burning Rock Biotech Co., Ltd., Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Daping Hospital of Army Medical University, Chongqing, China
Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
OrigiMed Shanghai Co., Ltd., Shanghai, China
Show Author Information

Abstract

Stage Ⅲ non-small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage Ⅲ NSCLC patients to receive consultation with a multiple disciplinary team, which allows the development of a proposal for clinical diagnosis and treatment. In this consensus, stage Ⅲ NSCLC is divided into two types (operable and inoperable) according to different clinical conditions. Resectable NSCLC is further subdivided into two conditions (with or without driver genes). For each clinical scenario, this consensus emphasizes that the foundation of any medical decisions regarding the optimal diagnostic or therapy procedure is scientific evidence from clinical research. Finally, based on the level of evidence and strength of recommendations, this consensus provides recommendations for the management of stage Ⅲ NSCLC from six perspectives. The objective of this consensus is to help clinicians choose the best treatment and promote the standardization of stage Ⅲ NSCLC diagnosis and treatment in China.

Keywords

consensusmultiple disciplinary comprehensive treatmentstage Ⅲ non-small cell lung cancer

References

[1]

Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non – small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 2007;57(3):253–60. https://doi.org/10.1016/j.lungcan.2007.03.012
Crossref Google Scholar
[2]

Mcphail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112(1S):S108–15. https://doi.org/10.1038/bjc.2015.49
Crossref Google Scholar
[3]

Moor S, Leung B, Wu J, Ho C. Real-world treatment of stage Ⅲ NSCLC: the role of trimodality treatment in the era of immunotherapy. J Thorac Oncol. 2019;14(8):1430–9. https://doi.org/10.1016/j.jtho.2019.04.005
Crossref Google Scholar
[4]

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009
Crossref Google Scholar
[5]

Mosmann MP, Borba MA, De Macedo FP, Liguori AAL, Villarim Neto A, Lima KC. Solitary pulmonary nodule and 18 F – FDG PET/CT. Part 1: epidemiology, morphological evaluation and cancer probability. Radiol Bras, 2016;49(1):35-42. https://doi.org/10.1590/0100-3984.2014.0012
Crossref Google Scholar
[6]

Chinese Anti-Cancer Association, Committee of Lung Cancer Society, Lung Cancer Group of Oncology Branch, Chinese Medical Association. Chinese expert consensus on the multidisciplinary clinical diagnosis and treatment of stage Ⅲ non – small cell lung cancer(2019). Chin J Oncol. 2019;41(12):881–90.
Google Scholar
[7]

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85. https://doi.org/10.1056/nejmoa2202170
Crossref Google Scholar
[8]

Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage Ⅲ A-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase Ⅱ study. J Clin Oncol. 2019;37(25):2235–45. https://doi.org/10.1200/jco.19.00075
Crossref Google Scholar
[9]

Lyu C, Fang W, Jiao W, Ma H, Wang J, Xu S, et al. 81MO – osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage Ⅱ -Ⅲ B lung adenocarcinoma (NEOS): updated results. Ann Oncol. 2022;33(2S):S71–8.
Crossref Google Scholar
[10]

Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol,2021,17(31):4045-55, https://doi.org/10.2217/fon-2021-0549
Crossref Google Scholar
[11]

Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-Ⅲ A (N1-N2) EGFR-mutant NSCLC (ADJUVAN/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139-48. https://doi.org/10.1016/s1470-2045(17)30729-5
Crossref Google Scholar
[12]

Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-Ⅲ A (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase Ⅲ trial. J Clin Oncol. 2021;39(7):713–22. https://doi.org/10.1200/jco.20.01820
Crossref Google Scholar
[13]

Yue DS, Xu SD, Wang Q, Li X, Shen Y, Zhao H, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage Ⅲ A EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6(11):863–73. https://doi.org/10.1016/s2213-2600(18)30277-7
Crossref Google Scholar
[14]

Pennell NA, Neal JW, Chaft JE, Azzoli CG, Janne PA, Govindan R, et al. SELECT: a phase Ⅱ trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol. 2019;37(2):97–104. https://doi.org/10.1200/jco.18.00131
Crossref Google Scholar
[15]

He JX, Su CX, Liang WH, Xu S, Wu L, Fu X, et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-Ⅲ A EGFR-mutant non – small – cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021;9(9):1021–9. https://doi.org/10.1016/s2213-2600(21)00134-x
Crossref Google Scholar
[16]

He QH, Liu J, Cai XY, He M, Li C, Liang H, et al. Comparison of first-generation EGFR – TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations. Transl Lung Cancer Res. 2021;10(11):4120–9. https://doi.org/10.21037/tlcr-21-649
Crossref Google Scholar
[17]

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–23. https://doi.org/10.1056/nejmoa2027071
Crossref Google Scholar
[18]

Xu ST, XI JJ, Zhong WZ, Mao WM, Wu L, Shen Y, et al. The unique spatial -temporal treatment failure patterns of adjuvant gefitinib therapy: a post hoc analysis of the ADJUVANT trial (CTONG1104). J Thorac Oncol. 2019;14(3):503–12. https://doi.org/10.1016/j.jtho.2018.11.020
Crossref Google Scholar
[19]

Yang XN, Yan HH, Wang J, Chu XY, Liu ZD, Shen Y, et al. Real-world survival outcomes based on EGFR mutation status in Chinese patients with lung adenocarcinoma after complete resection: results from the ICAN study. JTO Clin Res Rep. 2021;3(1):100257. https://doi.org/10.1016/j.jtocrr.2021.100257
Crossref Google Scholar
[20]

Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, et al. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR – mutated NSCLC. J Thorac Oncol. 2022;17(3):423–33. https://doi.org/10.1016/j.jtho.2021.10.014
Crossref Google Scholar
[21]

Koch AL, Vellanki PJ, Drezner N, Li X, Mishra-Kalyani PS, Shen YL, et al. FDA approval summary: osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative project orbis review. Clin Cancer Res. 2021;27(24):6638–43. https://doi.org/10.1158/1078-0432.ccr-21-1034
Crossref Google Scholar
[22]

Liu SY, Zhang JT, Wu YL. What we have learned from adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer. J Clin Oncol. 2022;40(3):217–20. https://doi.org/10.1200/jco.21.02443
Crossref Google Scholar
[23]

Liu SY, Bao H, Wang Q, Mao WM, Chen Y, Tong X, et al. Genomic signatures define three subtypes of EGFR-mutant stage Ⅱ-Ⅲ non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat Commun. 2021;12(1):6450. https://doi.org/10.1038/s41467-021-26806-7
Crossref Google Scholar
[24]

Felip E, Altorki N, Zhou CC, Csoszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage I B – Ⅲ A non – small – cell lung cancer (IMpower010): a randomised, multicentre, open – label, phase 3 trial. Lancet. 2021;398(10308):1344–57. https://doi.org/10.1016/s0140-6736(21)02098-5
Crossref Google Scholar
[25]

Paz-Ares L, O’Brien MER, Mauer M, Dafni U, Oselin K, Havel L, et al. VP3-2022-Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC)following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase Ⅲ EORTC-1416-LCG/ETOP 8-15-PEARLS/KEYNOTE-091 study. Ann Oncol. 2022;33(4):451–3. https://doi.org/10.1016/j.annonc.2022.02.224
Crossref Google Scholar
[26]

Jassem J, De Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC. J Thorac Oncol. 2021;16(11):1872–82. https://doi.org/10.1016/j.jtho.2021.06.019
Crossref Google Scholar
[27]

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. https://doi.org/10.1056/nejmoa1709937
Crossref Google Scholar
[28]

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC. N Engl J Med. 2018;379(24):2342–50. https://doi.org/10.1056/nejmoa1809697
Crossref Google Scholar
[29]

Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares LG, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage Ⅲ NSCLC: an update from the PACIFIC trial. J Clin Oncol. 2021;39(15S):Abstr8511. https://doi.org/10.1200/jco.2021.39.15_suppl.8511
Crossref Google Scholar
[30]

Zhang T, Bi N, Zhou ZM, Chen D, Feng Q, Liang J, et al. The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy. J Thorac Dis. 2020;12(8):4347–56. https://doi.org/10.21037/jtd-20-2137
Crossref Google Scholar
[31]

Walraven I, Damhuis RA, Ten Berge MG, Rosskamp M, van Eycken L, de Ruysscher D, et al. Treatment variation of sequential versus concurrent chemoradiotherapy in stage Ⅲ non – small cell lung cancer patients in The Netherlands and Belgium. Clin Oncol (R Coll Radiol). 2017;29(11):e177–85, https://doi.org/10.1016/j.clon.2017.07.012
Crossref Google Scholar
[32]

Wu YL, Zhou Q, Chen M, Jiang O, Hu D, Lin Q, et al. LBA43-GEMSTONE-301: a randomized, double-blind, placebo-controlled, phase Ⅲ study of sugemalimab in patients with unresectable stage Ⅲ non-small cell lung cancer (NSCLC)who had not progressed after concurrent or sequential chemoradiotherapy (CRT). Ann Oncol. 2021;32(5S):S1321. https://doi.org/10.1016/j.annonc.2021.08.2122
Crossref Google Scholar
[33]

Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage Ⅲ non -small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(2):209–19. https://doi.org/10.1016/s1470-2045(21)00630-6
Crossref Google Scholar
[34]

Garassino MC, Mazieres J, Reck M, et al. 108MO-Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage Ⅲ, unresectable NSCLC (PACIFIC-6). Ann Oncol. 2022;33(2S):S81–8.
Crossref Google Scholar
[35]

Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631–42. https://doi.org/10.1002/cpt.982
Crossref Google Scholar
[36]

Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino M, et al. 1171MO-PACIFIC-R real-world study: treatment duration and interim analysis of progression-free survival in unresectable stage Ⅲ NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 2021;32(5S):S939–40. https://doi.org/10.1016/j.annonc.2021.08.1775
Crossref Google Scholar
[37]

Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage Ⅲ non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 2021;7(9):1351-9, https://doi.org/10.1001/jamaoncol.2021.2301
Crossref Google Scholar
[38]

Peters S, De Ruysscher D, Dafni U, Felip E, Guckenberger M, Vansteenkiste JF, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: the ETOP NICOLAS phase Ⅱ trial. J Clin Oncol. 2018;36(15S):Abstr8510, https://doi.org/10.1200/jco.2018.36.15_suppl.8510
Crossref Google Scholar
[39]

Ross HJ, Kozono DE, Urbanic JJ, Williams TM, Dufrane C, Bara I, et al. Phase Ⅱ trial of atezolizumab before and after definitive chemoradiation for unresectable stage ⅢNSCLC. J Clin Oncol. 2018;36(15S):TPS8585, https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585
Crossref Google Scholar
[40]

Wan JCM, Massie C, Garcia – Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38. https://doi.org/10.1038/nrc.2017.7
Crossref Google Scholar
[41]

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432–7. https://doi.org/10.1038/s41586-021-03642-9
Crossref Google Scholar
[42]

Kris MG, Grindheim JM, Chaft JE, Lee J, Johnson B, Rusch V, et al. 1O-Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients(pts)with NSCLC. Ann Oncol. 2021;32(7S):S1373. https://doi.org/10.1016/j.annonc.2021.10.017
Crossref Google Scholar
[43]

Zhou CC, Das THAKURM, Srivastava MK, Zou W, Xu H, Ballinger M, et al. 2O-IMpower010: biomarkers of disease-free survival (DFS)in a phase Ⅲ study of atezolizumab(atezo) vs best supportive care (BSC)after adjuvant chemotherapy in stage IB-Ⅲ A NSCLC. Ann Oncol. 2021;32(7S):S1374. https://doi.org/10.1016/j.annonc.2021.10.018
Crossref Google Scholar
[44]

Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat Cancer. 2020;1(2):176–83. https://doi.org/10.1038/s43018-019-0011-0
Crossref Google Scholar
[45]

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394–403. https://doi.org/10.1158/2159-8290.cd-17-0716
Crossref Google Scholar
[46]

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early – stage lung cancer evolution. Nature,2017;545(7655):446-51. https://doi.org/10.1038/nature22364
Crossref Google Scholar
[47]

Chen KN, Zhao H, Shi YB, Yang F, Wang LT, Kang G, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin Cancer Res. 2019;25(23):7058–67. https://doi.org/10.1158/1078-0432.ccr-19-1213
Crossref Google Scholar
[48]

Peng M, Huang Q, Yin W, Tan S, Chen C, Liu W, et al. Circulating tumor DNA as a prognostic biomarker in localized non – small cell lung cancer. Front Oncol. 2020;10:561598. https://doi.org/10.3389/fonc.2020.561598
Crossref Google Scholar
[49]

Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021;12(1):6700. https://doi.org/10.1038/s41467-021-27022-z
Crossref Google Scholar
[50]

Xia L, Mei JD, Kang R, Deng S, Chen Y, Yang Y, et al. Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUN-GCA-1). Clin Cancer Res. 2021;28(15): 3308–17. Online ahead of print. https://doi.org/10.1158/1078-0432.CCR-21-3044
Crossref Google Scholar
[51]

Li N, Wang BX, Li J, Shao Y, Li M, et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage Ⅰ to Ⅲ A non-small cell lung cancer. Cancer. 2022;128(4):708–18. https://doi.org/10.1002/cncr.33985
Crossref Google Scholar
Medicine Advances
Volume 1 Issue 1,
March 2023
Pages 3-13
DOI: 10.1002/med4.7
Cite this article:
Wu Y-L, Lu S, Zhou Q, et al. Expert consensus on treatment for stage Ⅲ non-small cell lung cancer. Medicine Advances, 2023, 1(1): 3-13. https://doi.org/10.1002/med4.7

723

Views

94

Downloads

2

Crossref

Altmetrics
Received: 16 February 2023
Accepted: 21 February 2023
Published: 24 March 2023
© 2023 The Authors. Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, providedthe original work is properly cited.
Return